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Title 
Emerging molecular target antagonists for the treatment of biliary tract cancer 
 
Abstract  
Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence 
but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of 
effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is 
cisplatin/gemcitabine combination, whereas no standard in 2
nd
-line has been defined. Hence, the current goal 
is to better understand the biology of BTCs, discovering new treatment methods and improving clinical 
outcomes. 
Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular 
signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical 
trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. 
Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. 
Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be 
reviewed. 
Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted 
treatments under evaluation. In addition, innovative trial design will allow to offer a chance for tailored 
medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their 
histology. 
 
Manuscript 
1-Background  
Biliary tract cancer (BTC) is a heterogeneous group of tumors arising from the epithelial lining of the biliary 
tree. The classification is based according to the anatomical location; BTC includes gallbladder cancer (GBC) and   
cholangiocarcinoma (CCA); the latter is further divided into intrahepatic (IH-CCA), and extrahepatic (EH-CCA), 
which includes EH-CCA perihilar (PCCA) and distal CCA (DCCA). IH-CCAs arise above the second order bile ducts, 
whereas PCCAs are located between the insertion of the cystic duct and the second order bile ducts, and 
DCCAs are located below the insertion of the cystic duct [1, 2]. 
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Even though GBC, intrahepatic, perihilar and distal extrahepatic CCA are grouped as BTCs, their clinical 
presentation, pathobiology and management are different, and they should be viewed as separate entities. 
Despite being considered an infrequent cancer in the Western world, with an incidence of 1-2 cases every 
100,000 inhabitants, BTCs are extremely common in South America and in some areas of Asia, with up to 96 
cases/100,000 [3]. 
Histologically, more than 95% of BTCs are adenocarcinomas, often poorly differentiated. About 10% of EH-CCA 
are well differentiated papillary cancers, but mucinous (5%) and squamous cancers (2%) are also described [4]. 
Several classifications have been proposed for IH-CCA owing to its highly heterogeneity. The two main 
histological subtypes are bile ductular type (mixed), arising from small intrahepatic bile ducts, and bile duct 
type (mucinous), arising from large intrahepatic bile ducts. These differences are also reflected in different 
molecular characteristics [5]. Notably, bile ductular type IH-CCAs share clinicopathological similarities with 
cytokeratin (CK) 19-positive hepatocellular carcinoma (HCC), and the bile duct type IH-CCAs share phenotypic 
traits with PCCA and pancreatic cancers [6]. 
Beyond the differences, BTC have common features, such as a highly desmoplastic reaction, rich tumor 
microenvironment, and profound genetic heterogeneity, all contributing to the development of drug resistance 
and almost complete absence of curative therapies for metastatic disease. 
The vast majority of BTC (70%) occurs sporadically. Nevertheless, several pathologic conditions have been 
determined as possible risk factors such as Primary Sclerosing Cholangitis (PSC), choledochal cysts, parasitic 
infestation, and viral hepatitis B and C. Potential risk factors with less evidence are diabetes, alcohol, smoking, 
obesity and specific genetic polymorphisms [7]. Therefore, although a single trigger cannot be identified, 
different environmental, genetic and social factors may be rather involved and justify heterogeneous 
geographic distribution. 
 
Most patients with early stage disease are asymptomatic and diagnosing BTC at an early stage remains a 
challenge owing to its ‘silent’ clinical presentation, difficult to access anatomical location, and highly 
desmoplastic, paucicellular nature, which limits the sensitivity of cytological and pathological diagnostic 
approaches.  
Surgery is the preferred treatment option for localized BTC, but only a minority of patients (approximately 
35%) has early stage disease that is amenable to surgical resection with a curative intent. Survival after radical 
surgery generally depends on margin status (negative-R0 or positive-R1-R2 status), vascular invasion and lymph 
node involvement. Even after R0 resection 3-years survival rate is approximately 40-60%, and it can be lower in 
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case of lymph node positivity [8]. 
The unfavorable prognosis of recurrent disease drove efforts to lower the rate of relapse through 
postoperative adjuvant therapy. So far, the great part of the available literature was made of retrospective, 
non-randomized studies and meta-analyses: the majority took in consideration heterogeneous populations of 
patients, treated with different systemic drugs with or without radiotherapy. Recently, following the 
presentation of the preliminary results of the BILCAP study, a standard of care for adjuvant treatment is 
available. In this randomized phase III trial, postoperative capecitabine was compared to surveillance: the 
primary endpoint of the study was formally not met, despite a difference of 15 months in the median overall 
survival (mOS) estimated values (51 versus 36 months, p = 0.097). However, mOS was significantly higher in the 
chemotherapy arm both after sensitivity analyses and in the per protocol analysis [9]. 
For patients with advanced-stage or unresectable disease, the available systemic therapies are of limited 
effectiveness: the mOS with the current standard-of-care regimen (gemcitabine and cisplatin) is <1 year [10] 
and a probability to outlive 5 years is about 5% [11]. 
 
2-Medical need 
Randomized trials have shown that systemic chemotherapy increases survival and improves quality of life (QoL) 
in patients with metastatic BTC as compared with best supportive care (BSC). In the study by Glimelius, 90 
patients with metastatic or locally advanced pancreatic carcinoma or BTC have been randomly assigned to 5-
fluorouracil (5-FU) -based chemotherapy or BSC. A clear benefit of chemotherapy on both mOS (6 vs 2.5 
months in BSC group p< 0.01) and QoL was demonstrated [12]. More recently, modified gemcitabine and 
oxaliplatin (mGEMOX) proved a significant improvement in mOS not only over BSC, but also over 5-FU/folinic 
acid in unresectable GBC (9.5, 4.6 and 4.5 months respectively)[13]. 
The majority of trials in the metastatic setting were performed with fluoropyrimidine or gemcitabine 
monotherapy or in combination with other cytotoxic agents. 5-FU as single agent yields a variable response 
rates (RR) from 10% to 40%. The combination of 5FU with other drugs (etoposide, interferon, cisplatin and 
oxaliplatin) has proved moderate efficacy, limited overall survival (OS) benefit, and a significantly greater 
toxicity profile. Since the late 90s, the adoption of gemcitabine as the standard of care for patients with 
pancreatic cancer led to interest in its use for hepatobiliary tumors. As a single agent, gemcitabine has shown 
RRs ranging from 0% to 30%, whereas its association with other agents has determined advantages in survival 
and RRs (up to 41%) [14]. In 2007 a pooled analysis of 104 trials in advanced BTC, demonstrated the superiority 
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of combination therapy compared to monotherapy in RR and tumor-control-rate (TCR). Subgroup analysis also 
underlined that gemcitabine and platinum association had significantly higher response and TCRs compared to 
fluoropyrimidine/gemcitabine monotherapy or fluoropyrimidine plus platinum regimens [15]. 
Suggestions from this meta-analysis were turned into a standard of care by Valle’s Phase III ABC- 02 trial. Four 
hundred and ten patients with locally advanced or metastatic CCA, GBC and ampullary carcinoma were 
randomly assigned to receive gemcitabine alone (1000 mg/m2 days 1, 8, 15 q 28) vs gemcitabine and cisplatin 
(1000 mg/m2 + 25 mg/m2 days 1, 8 q 21) for up to 24 weeks of treatment. After a median follow-up of 8.2 
months, mOS, that was the primary endpoint of the study, was statistically improved in the combination arm 
(11.7 vs. 8.1 months; p < 0.001). The benefit was preserved across the subgroups according to primary tumor 
site, median progression-free-survival (mPFS) was improved (8.0 months vs. 5.0 months; p < 0.001), without 
significant increase in toxicity. [10]. Following the results of this trial, a definite standard regimen for a disease 
that has been “orphaned” for too long, was finally provided. Equivalent results have been replicated in the 
japanese population [16]. Other combination schemes have also been evaluated as first line treatment in phase 
II trials [17-19]. Among these, gemcitabine and oxaliplatin (GEMOX) is widely used in clinical practice for its 
good response rate and favorable toxicity profile, although a direct comparison with the standard of care is 
lacking [13, 20]. 
Following a meta-analysis of the English and Japanese randomized trials, single agent gemcitabine is a 
recommended option only for patients with Performance Status (PS) 2 according to Eastern Cooperative 
Oncology Group (ECOG) scale [21].  
After the failure of the 1
st
 line therapy, approximately half of the patients still have a good PS and satisfactory 
organ function [22], but the advantages of 2
nd 
line therapy are still unclear. In a large retrospective analysis, 196 
patients who received 2
nd
 line treatment after gemcitabine and cisplatin/oxaliplatin, were analyzed. The most 
common regimens used were 5-FU/folinic acid, FOLFIRI, XELIRI, FOLFOX, XELOX, 5-FU and cisplatin: globally, 
the outcome was poor, the mPFS and OS being 3.2 and 6.7 months, respectively, and no chemotherapy 
regimen proved superiority over the others [23]. In another Italian retrospective analysis, PS emerged as the 
most important prognostic factor to select the patients that may benefit from 2
nd
 line treatment [24]. 
 
3-Existing treatment  
In the past decade we have entered the era of targeted therapies: this strategy has modified the therapeutic 
approach of many cancers but the first attempts of using targeted treatments in BTCs have been so far 
unsatisfactory. Here, we revise the first studies that have explored targeted therapies in BTC.  
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• 3.1 EGFR family pathway 
Epidermal growth factor receptor (EGFR) is mutated and overexpressed in cancer human samples. EGFR is 
extensively represented in BTC, being expressed in 100% of IH-CCAs, 52.6% of EH-CCAs, and 38.5% of GBCs. 
[25]. Mutations have been found in up to 15% of BTCs [26, 27]. EGFR activation triggers the Mitogen Activated 
Proteine Kinases (MAPK)–ERK pathway, an oncogenic signalling pathway in cancer: it donates a proliferative 
advantage to cancer cell, contributes to progression through epithelian-mesenchymal transition (EMT) and 
leads to a poor clinical outcome [28, 29]. In preclinical studies, EGFR inhibitors tested in combination with 
chemotherapy have shown promising activity, providing a strong preclinical rationale for anti-EGFR therapy in 
BTC. Different strategies targeting EGFR have been studied such as tyrosine kinase inhibitors (TKIs) or 
monoclonal antibodies (mAbs) alone or in association with chemotherapy. 
Erlotinib, a selective, reversible, orally-active EGFR inhibitor, after promising results in several phase II studies, 
failed to confirm its superiority in OS in a large phase III study. Compared to the combination of GEMOX, the 
addition of erlotinib in patients with newly diagnosed metastatic BTC significantly increased RR (40% vs 21%; 
p=0.005) but mPFS and OS were not increased (4.2 vs 5.8 months p=0.087 and 9.5 months in both arms, 
p=0.611 respectively). Subgroup analyses showed that in patients with CCA the addition of erlotinib prolonged 
mPFS (5.9 months vs 3.0 months; HR 0.73, 95% CI 0.53–1.00; p=0.049) [30]. 
Cetuximab is a mAb targeting EGFR, evaluated in combination with chemotherapy in BTC in several phase II 
trials. In a phase II study of cetuximab in combination with GEMOX, the treatment achieved a mPFS of 8.3 
months and OS of 12.7 months, with high RR [31]. Following randomized trials failed to demonstrate a 
significant benefit of the GEMOX and cetuximab combination. In the BINGO study, cetuximab was tested in the 
1
st
 line setting in addition to GEMOX vs GEMOX alone. Despite being well tolerated, cetuximab did not 
significantly improve outcomes: mPFS was 6.1 months with cetuximab and 5.5 months without cetuximab, 
while mOS was 11.0 months with cetuximab and 12.4 months without cetuximab [32]. In a similar study in the 
Asiatic population, mPFS was 6.7 months with cetuximab and 4.1 months without cetuximab (p = 0.05), while 
mOS was 10.6 months vs 9.8 months respectively (p = 0.91). KRAS mutations, that are a well-known negative 
predictive factor of response to anti-EGFR mAbs, were identified in 36% of tumors, and did not affect the 
overall response rate (ORR) or mPFS [33]. 
Panitumumab, a fully human antibody against EGFR, has been tested in combination with chemotherapy in 
non-randomized and randomized, phase II trials. In particular, in the Vecti-BIL trial advanced BTC patients were 
selected upfront for KRAS mutational status. The study revealed that the addition of panitumumab to GEMOX 
compared to GEMOX alone did not significantly improve mPFS, (5.3 months in experimental arm vs 4.4 months 
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 6 
in control arm), neither OS (10.2 months in experimental arm vs 9.9 months in control arm) in KRAS wild type 
(WT) BTC patients [34].  
Despite the results of a recent meta-analysis suggesting a potential role of anti-EGFR therapy in prolonging PFS 
and RR, the current evidence does not support its use in BTC [35]. 
• 3.2 MEK pathway 
Targeting the RAS/RAF/MEK/ERK pathway, a major player in the cellular processes, including proliferation and 
apoptosis, is thought to be a winning strategy in many cancers including BTC.  
The second-generation, uncompetitive inhibitor of MEK 1/2 - selumetinib - was investigated in a phase II study 
of 28 advanced BTC patients. Median PFS was 3.7 months and the mOS was 9.8 months, with a 12% of ORR 
[52]. Recently a Phase Ib trial has tested the pharmacokinetics and toxicity profile of selumetinib in 
combination to cisplatin and gemcitabine. Other trials are needed to demonstrate its applicability in clinical 
practice [53]. 
Another uncompetitive inhibitor of MEK 1/2, binimetinib, after encouraging results in safety and activity during 
phase I studies [54], is currently under evaluation in phase II studies (NCT02151084, NCT01828034). 
Recently, the open-label, multicentre, single-arm trial, evaluating pazopanib - an orally available multikinase 
inhibitor of VEGF (vascular endothelial growth factor) receptor, PDGF (platelet-derived growth factor) receptor, 
c-KIT (stem-cell growth factor receptor), fibroblast growth factor receptor (FGFR) and RAF - in addition to 
trametinib - an orally available highly specific inhibitor of MEK 1 and MEK 2 - showed discouraging results. 
Despite the trend towards increased 4-month PFS, the difference did not reach statistical significance. The mOS 
was 6.4 months (95% CI: 4.3–10.2) and the ORR was 5% (95% CI: 0.13–24.9%) [55]. 
• 3.3 VEGF 
The vascular endothelial growth factor (VEGF) pathway promotes tumor growth - by angiogenesis and vascular 
permeability - in several tumors including BTC [36]. In CCA, VEGF expression is reported in about 30-40% of 
cases and is correlated with lymphnode metastasis and poor prognosis [37, 38]. VEGF expression is reported in 
50% of GBC and also in this sub-group a poor prognosis is observed [39]. Based on preclinical and clinical data 
supporting a VEGF-targeted approach, several studies have evaluated the effectiveness and applicability of 
targeted therapy (bevacizumab, sorafenib, cediranib, vandetanib) in metastatic BTC, providing only limited 
information, principally because of their phase II design. Therefore, the role of antiangiogentic agents in the 
treatment of BTC is not well defined. 
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 7 
Bevacizumab is a recombinant humanized mAb whose efficacy has been tested in patients affected by 
advanced BTC. In two studies it was tested in combination with erlotinib and in sequence with gemcitabine and 
oxaliplatin, without favorable results [40, 41]. More recently, a small phase II study evaluated the combination 
of gemcitabine, capecitabine, and bevacizumab in a first-line setting, showing a mPFS and mOS similar to those 
observed with standard chemotherapy (8.1 months and 11.3 months, respectively) [42]. Larsen et al. recently 
presented the results of a phase II trial of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-
line setting in 50 BTC patients. Median PFS was 3.6 months and mOS was 6.4 months [43]. To date, the role of 
bevacizumab on BTC has been evaluated only in single-arm studies, with no randomized study performed. 
Cediranib is a potent inhibitor of the VEGF receptor tyrosine kinases -also directed against PDGF receptors and 
c-KIT being investigated in a recent phase II study [44]. Patients were randomized to receive cisplatin and 
gemcitabine plus either cediranib or placebo. Cediranib did not significantly improved mPFS (7.7 months in the 
cediranib arm vs. 7.4 months in the placebo arm). There was a trend towards longer OS in the experimental 
arm compared to placebo (14.1 vs 11.9 months, respectively) [45]. 
For definitive conclusions, we will have to wait for the results of the ongoing phase II trial, investigating 
cediranib in combination with modified FOLFOX6 in advanced BTC (NCT01229111). 
Sorafenib is an oral multikinase inhibitor directed against VEGF receptors and PDGF receptor-β, and blocking 
downstream intracellular serine/threonine kinases, like Raf-1, WT and mutant B-Raf. 
After the defeats in monotherapy in several studies, the more recent conducted by Luo et al [46], Sorafenib 
was evaluated in combination with standard chemotherapy. 
First, Moehler et al. investigated Sorafenib in the first line setting, treating patients with gemcitabine with 
either sorafenib or placebo. In this study, longer mPFS and OS were found in the gemcitabine plus placebo arm 
[47]. Then, a randomized, double-blinded, multicenter phase II trial investigating a combination of gemcitabine, 
cisplatin with either sorafenib or placebo demonstrated no significant difference in mPFS and mOS between 
the two arms [48]. Finally, a small trial conducted by Lee et al. showed that the addition of sorafenib to 
gemcitabine and cisplatin did not improve efficacy over historical data, but there was an increase of toxicity 
[49]. 
Sunitinib is another oral small molecular-targeted drug inhibiting several intracellular and receptor protein 
kinases, including VEGF and PDGF receptors, c-KIT, and rearranged during transfection (RET). In the only 
available phase II study, the role of sunitinib was investigated as a second-line treatment in advanced BTC 
demonstrating only marginal efficacy; ORR was 8.9 % and mPFS was 1.7 months [50]. 
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Vandetanib is an orally active, multikinase inhibitor targeting VEGF receptor 2, EGFR and RET kinase. In the 
Italian "VanGogh" study, 165 BTC patients chemotherapy-naive were randomized into three groups: 
vandetanib monotherapy, vandetanib plus gemcitabine and gemcitabine plus placebo. Median PFS was 105 
days (95 % CI 72–155), 114 days (95 % CI 91–193), and 148 days (95 % CI 71–225) respectively, while mOS was 
228 days (95 % CI 190–364), 284 days (95 % CI 213–359), and 307 days (95 % CI 254–523) for the three arms 
respectively. Thus, vandetanib alone or in association with gemcitabine did not demonstrate any superiority 
when compared with gemcitabine alone [51]. 
In conclusion, the role of VEGF inhibition in addition to chemotherapy for patients with advanced BTCs remains 
still investigational, but increasingly burdened by the absence of a biomarker of efficacy for VEGF inhibitors. 
 
4-Market review 
Throughout the therapeutic course of BTC patients, complications are a constant. Infections, sepsis and 
cholangitis often undermine patients’ health. Furthermore, chemotherapy is associated with high rate of side 
effects that requires spending of many economic resources.  
We have considered two cost-effectiveness analysis conducted in USA and Japan. They evaluate cost-
effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with 
gemcitabine alone. Despite being two comparable analyses in different populations, their conclusions are 
opposite; Roth et al. demonstrated that cisplatin and gemcitabine combination was a cost-effective alternative 
to gemcitabine monotherapy. Tsukiyama et al., on the contrary, suggested that gemcitabine monotherapy was 
a better treatment strategy for advanced BTC. These different conclusions may be due to varying health care 
conditions and  different long-term palliative care cost between the countries. 
Surprisingly, in both studies the majority of the resources were employed for supportive and palliative care 
rather than for drugs [56, 57]. 
For these reasons, systemic treatments are required not only to prolong survival, but also to limit palliative 
interventions. Recently, immunotherapy and target therapies have demonstrated to increase QoL and to be 
associated to lower rates of side effects in several cancer types as compared to chemotherapy [58-60]. For 
these reasons, alternative treatment strategies are also strongly encouraged in BTC patients. 
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5-Current research goals 
Carcinogenesis is a multistep process encountering imbalance between proliferative and inhibitory stimuli, 
dysregulation of apoptotic signals and abnormal response to angiogenetic factors which are responsible for 
invasion and metastatization events [61]. It involves specific cell genome derangements that contribute to the 
selective growth advantage of cancer. Specific pathways govern cell fate through proliferation, cell survival, 
differentiation, epigenetic changes and maintenance of genome integrity [62]. 
The genomic heterogeneity of BTC is well-known. As previously discussed, it’s not only related to the diverse 
anatomical location of the tumor but also to etiology, the various risk factors and associated pathologies. 
Interestingly, mutations in TP53 responsible for genome integrity are very common in all subgroup of BTC but 
are more often observed in liver-fluke related CCA [63]. These differences will need to be considered when 
assessing outcome and in devising therapeutic strategies for CCA and GBC [2, 61, 64-67]. Advances in genome-
wide technologies have made feasible the discovery of other possible targetable or actionable molecular 
alterations in BTC. Precision therapy for this group of tumors is subordinated to an enhanced understanding of 
genetic and molecular alteration for each subtype. 
 
6-Scientific rationale and molecular pathogenesis  
• 6.1 Proliferation and cell survival.  
Several growth pathways are implicated in arising and progression of BTCs. Here we revise the most promising 
preclinical evidences that could, in the near future, have a clinical counterpart. 
ErbB family, that includes four different receptors (ErbB1 or EGFR, ErbB2 or HER-2/neu, ErbB3 and ErbB4 ), 
have a main role in carcinogenesis processes and represents the most extensively mutated pathway of the GBC 
samples [68]. We have already introduced the role of EGFR and its clinical implications. 
Human epidermal growth factor receptor 2 (HER2) amplification has been observed in BTCs patients with a 
prevalence in EH-CCA (about 20%), GBC (9.8%) and a rare incidence in IH-CCA. The prognostic meaning of HER2 
has not yet been completely clarified but could become a relevant predictive factor [68, 69]. 
KRAS mutations occur in BTC and the reported incidence is 7-47%. It is usually associated with the alteration of 
other factors, such as EGFR, HER2 or MET [68, 70]. A recent work showed poor prognosis for KRAS mutated 
CCA that is more pronounced in the subgroup with transcriptional enrichment of genes that regulate 
proteasome activity [71]. 
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Some studies reported BRAF mutations in a percentage between 0% and 22%. In a large cohort, BRAF V600E 
mutation was observed in 5.9% of GBC, 3% of IH-CCA and 0% of EH-CCA and no clear correlation with prognosis 
was detected [72, 73]. 
Recently, ARAF mutation (ARAFm), a member of the RAS family, has been reported in 11% of IH-CCA iCCA. 
ARAFm leads to an increased basal and inducible activity when compared to WT protein. Further studies need 
to investigate the oncogenic potential of this new target. [74]. 
ROS1 fusion proteins have been recently implicated in CCA carcinogenesis. The fused-in-glioblastoma-c-ros-
oncogene 1 (FIG-ROS) was found in 14-16% of EH-CCA [75] and it mediated cancerogenesis in KRAS dependent 
mode with a high aggressiveness [76]. 
The expression level of hepatocyte growth factor (HGF) receptor (also known as c-Met) is amplificated either in 
CCA and GBC. Miyamoto analyzed 247 patients and noted MET high expression in 11.7% of IH-CCA and 16.2% 
in EH-CCA. MET seems to play a central role in carcinogenesis through the protection from apoptosis and 
promoting angiogenesis and tumor invasion. In CCA it is associated with EGFR expression and represents a poor 
prognostic factor. Moreover, it could be linked to acquired resistance to EGFR or HER2 inhibitors [77, 78]. 
FGFR is a tyrosine kinase receptor involved in numerous cellular process including proliferation, angiogenesis 
and tissue repair. Disruption of this pathway has been implicated as driver event in biliary cancer formation. 
Fusions of FGFR gene have been reported in some cancer type; in BTC several gene fusions have been 
described, the most frequent being FGFR2-BICC1 fusion. This new protein seems to have a higher incidence in 
female and a link with hepatitis infection. It is constitutively active and leading to the activation of MAPK and 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/ mammalian target of 
rapamycin (mTOR) pathways. Moreover, FGFR translocation may confer a survival benefit. Indeed, in a western 
dataset a superior cancer specific survival was observed in patients with FGFR2 translocation compared to non 
translocated patients (123 months vs 37 months) [65, 74, 79].  
Aberration in tumor suppressive gene phosphatase and tensin homolog (PTEN) has been correlated with 
clinical outcome. Indeed, PTEN loss has been associated with poor outcome in all BTC, particularly in 
combination with either activated Protein kinase B (PKB), also known as Akt or mTOR. However, genetic 
alteration in AKT genes, with normal level of PTEN, were associated with cancerogenesis but also with 
favorable prognosis. These findings suggest isolated AKT alteration could have an important role in the 
initiation of IH-CCA but not in progression of this subgroup [80-82]. 
Different pathways have been implicated in carcinogenesis and proliferative advantage in CCA. However, these 
pathways overlap in several points, providing a molecular reason for resistance to target therapies.  
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Besides, not every cancer has a proliferative signature. Sia et al., using an integrative molecular analysis 
technique, have identified gene signatures in IH-CCA and have correlated them with pathological features and 
clinical patients’ outcome. The authors describe two categories of IH-CCA: a proliferative class and an 
inflammatory class. The proliferative class, that accounts for 62% of cases, was typified by alterations in several 
oncogenes included in RAS-RAF-MEK-ERK or PIK3CA-AKT-mTOR signaling pathway, implicated in cell 
proliferation and cell survival, respectively.  
The inflammatory class showed activation of inflammatory pathways, overexpression of cytokines (i.e. IL-6) and 
signal transducer and activator of transcription 3 (STAT3). STAT3 is a mediator that modulates cell growth and 
survival while IL-6 is an inflammatory cytokine produces either by CCAs and cholangiocytes stimulated by an 
inflammatory noxa. IL-6 is involved in cell survival through upregulation of Mcl-1 via AKT-dependent 
mechanism. Mcl-1 mediates tumor necrosis factor-related apoptosis inducing ligand (TRAIL) resistance and cell 
survival. IL-6 is also implicated in upregulation of Mcl-1 through a STAT3 dependent mechanism [83, 84].  
• 6.2 Cell differentiation 
The Notch signaling pathway has a main role in cell differentiation, inflammation and carcinogenesis. Notch 
activation was implicated in de-differentiation of adult hepatocytes into precursors of IH-CCA. These studies 
not only show the high plasticity of liver cell but also change the traditional model according to which CCA cells 
derived from cholangiocytes or hepatic common progenitor cells [85]. These observations could be combined 
to Sia et al. data. In this work, the authors describe how gene signatures, especially the proliferation class 
one's, overlap with those identified in HCC. These data provides us a second model of CCA carcinogenesis; not 
only based on alteration of epithelial cells of biliary tree but also on de-differentiation of adult 
hepatocytes.[84].  
• 6.3 Epigenetic changes. 
Tumor cells may also acquire an advantage in survival and proliferation through epigenetic changes that lead to 
silencing of onco-suppressor genes. Mutations of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are among 
the most common genetic alteration in IH-CCA (14-36%) [70, 86], with unclear prognostic significance [87]. No 
mutations in these genes were observed in EH-CCA and GBC. Mutant IDH proteins lead to an abnormal 
enzymatic activity inducing to production of 2-hydroxyglutarate (2-HG) from α-ketoglutarate (αKG), which is 
considered an oncometabolite and causes epigenetic changes. Furthermore, deficiency in αKG inhibits activity 
of αKG-dependent dioxygenase and results in altered cell differentiation, survival and extracellular matrix 
maturation [88, 89]. Mutant IDH blocks liver progenitor cells that, as a result of altered hepatocyte response to 
hepatic injury, could lead to the development of malignant lesions. Indeed, a recent work has shown that 
mutant IDH blocks hepatocyte differentiation through the production of 2-HG and the suppression of HNF-4α, 
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the main regulator of hepatocytes identity and quiescence [90]. Farshidfar et al. have associated mutant IDH 
with a specific gene signature characterized by high mitochondrial and low chromatin modifier gene 
expression. Speculating about the significance of this signature is complex for the wide number of genes and 
processes involved. Potentially, the combination of anti-IDH targeted therapies with anti-mitochondrial activity 
drugs could be exploited in the future as a therapeutic strategy [91]. 
• 6.4 Angiogenesis and tumor environment. 
VEGF has a central role in carcinogenesis and it has been targeted in different malignancies. In CCA, VEGF 
expression is reported in about 30-40% of cases and is correlated with lymph node metastasis and poor 
prognosis [38]. VEGF expression is reported in 50% of GBC and also in this sub-group a poor prognosis is 
observed [39]. 
BTC have a characteristic hypovascular, desmoplastic stroma that plays an important role in tumor 
pathogenesis and is consisting of cancer associated fibroblasts (CAF) expressing α-smooth muscle actin (α-
SMA), activated macrophages and a fibrotic collagen rich extracellular matrix [92]. 
α-SMA positive CAFs are involved in cancer progression through production of matricellular proteins, growth 
factors, chemokines, and matrix metalloproteinases. Patients expressing high levels of α-SMA have poorer 
survival [93]. The desmoplastic matrix also allows the development of a niche fostering tumor spread rather 
than as a response to the anticancer treatments [94]. Transforming growth factor β (TGF- β) seems to be 
implicated in the generation of the niche. Indeed, preclinical models have demonstrated a reduction in fibrosis 
and tumor spread with TGF-β antagonist [95].CAFs produce numerous factors involved in autocrine and 
paracrine signalling that promote oncogenic processes like periostin, tenascin-c, thrombospandin 1, stromal 
cell derived factor 1 (SDF-1), HGF and Wnt inducible signalling protein-1v (WISP1) [93]. These interact with cell 
signalling pathways. For example, periostin interacts with tenascin-C, HGF and SDF-1, which bind to their 
respective receptors, integrin, MET and CXCR4 on CCA cells, leading to activation of the PIK3CA/AKT signalling 
pathway. 
Finally, desmoplastic stroma may be influenced also by sonic Hedgehog (Hh) signalling pathway. Preclinical 
models have disclosed the interplay between Hh and CAF through platelet-derivated growth factor BB [96].  
Cancer associated macrophages (CaM) are implicated in formation and maintaining of the stromal 
microenvironment and appear to have prognostic significance.  A high number of CD163+ macrophages in the 
stroma of resected IH-CCA correlates with poor disease-free survival [97]. 
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Desmoplastic stroma formation is also associated with increased level of IL-6 that promotes tumor growth via 
autocrine and paracrine mechanisms [93]. 
For all these reasons, targeting stromal factors involved in cholangiocarcinogenesis or improving drug delivery 
through the desmoplastic stroma are attractive targets for novel therapeutics. 
• 6.5 Immune system. 
In BTC, a number of clinical and epidemiological factors might predict the efficacy of immunotherapies. Several 
chronic infections, such as viral hepatitis and bacterial cholangitis, are established risk factors for 
cholangiocarcinoma. Notably, immunotherapies have shown promising efficacy in cancer associated with 
infections, probably thanks to the presentation of non-self or neoantigens related with infections [98]. 
Furthermore, in a patient subgroup of BTC with poor prognosis has been revealed had a high mutational load, 
resulting in abundant tumor-specific neoantigens, and enrichment for expression of immune-related genes, 
including genes encoding inhibitory immune-checkpoint proteins [65]. In these patients, immune-checkpoint 
inhibition could permit to overcome cancer related mechanism of immune-silencing. 
A central role in immune response is played by CaM that, through the production of soluble factor such as 
interleukins or cytokines, modulates anticancer immune response and maintain stromal environment [97]. 
In some small studies, programmed death-ligand 1 (PD-L1) expression has been evaluated on cancer specimens 
and on immune cells within the tumor microenvironment [99, 100]. PD-L1 is one of the most studied biomarker 
and levels of tumor PD-L1 expression have been associated with sensitivity to immune checkpoint inhibitor 
monotherapy in several tumor and they could predict response to the immunotherapies. 
 
7- Competitive environment and potential development issues 
• 7.1 HER2 
HER2 also belongs to the ErbB family of tyrosine kinases receptor and it is seems to be overexpressed in 
approximately 10% of GBC and 26.3% EH-CCA [25]. Given the efficacy of agents targeting HER2 in other cancers 
types, they were tested in BTC patients, nevertheless none improved outcomes so far. 
Lapatinib is a dual tyrosine kinase EGFR and HER2 inhibitor; it was tested in two phase II studies in patients 
with advanced BTC. The first one was conducted on hepatobiliary cancer patients including 19 BTC, reaching  
poor results (mPFS was 1.8 months and mOS was 5.2 months) and no objective responses [101]. Later, similar 
results have emerged from a phase II trial involving only BTC patients: the response was extremely poor (0%), 
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leading to premature discontinuation of the trial [102]. The role of Trastuzumab, a mAb that targets the HER2 
receptor, is so far not well defined in treatment of BTC. The only data available comes from a retrospective 
analysis in which Javle et al. studied BTC patients with HER2 genetic alterations or protein overexpression 
treated with HER2-directed therapy in combination with concurrent therapy of physician’s choice. Among the 
eight GBC patients who received trastuzumab, one patient experienced complete response (CR), four patients a 
partial response (PR), and three had stable disease (SD). The median duration of response in these patients was 
40 weeks. In contrast, among five CCA patients no response was observed and disease progression occurred 
during treatment with trastuzumab [103]. Likewise, in 2012 Law reported a case of a patient affected by HER2 
positive GBC, showing a dramatic response after nine weeks of treatment with trastuzumab and paclitaxel 
[104]. 
Neratinib, a more recent tyrosine kinase inhibitor HER2-directed is actually under evaluation in SUMMIT, an 
ongoing basket trial involving a variety of tumor types harboring HER2 mutations, including BTC 
(NCT01953926). Preliminary data, recently presented during the American Association for Cancer Research's 
Annual Meeting 2017 showed an ORR of 22% in BTC (9 patients) [105]. 
Similarly, in a phase II trial evaluating the efficacy of Afatinib - a potent, orally bioavailable ErbB Family Blocker 
– was tested in different malignancies including 5 BTCs presenting HER2 amplification [106]. As shown in table 
1, afatinib is currently under evaluation, in association with capecitabine, in a phase I/Ib trial addressed to 
patients with advanced refractory solid tumors, comprising pancreatic cancer and BTCs (NCT02451553) (Table 
1, New therapies under evaluation in biliary tract cancers). 
Given these contradictory outcomes, HER2-directed therapy remains an open chance of treatment for BTC 
patients with gene amplification, especially in GBC. A phase II trial of trastuzumab-emtansine is currently 
ongoing in HER2-positive BTC patients (NCT02999672) (Table 1).)  
 
• 7.2 PIK3CA/PTEN/AKT/mTOR pathway 
The PIK3CA/PTEN/AKT/mTOR pathway has drawn attention in last years as a target for new drugs 
development. About 12.5% of GBC patients have activating mutations of PIK3CA [107]. 
In a phase II Italian study, 39 patients with advanced and pre-treated BTC received everolimus - an mTOR 
inhibitor; mPFS was 3.2 months, and mOS was 7.7 months [108]. Since only patients who had received no more 
than one previous systemic chemotherapy regimen were enrolled, these results are at least in line with 
conventional 2
nd
-line chemotherapy results in advanced BTC, reporting a mPFS and mOS of 2.8 and 7.5 months 
respectively. 
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At the same time, in the Australian phase II study, everolimus was investigated in the first line setting in 
advanced BTC. Final results are not yet available, but preliminary findings are encouraging:  ORR of 12 % and  
mPFS of 6.0 months [109]. 
More extensive studies are needed to clarify the efficacy of mTOR inhibitors in the treatment of BTC. 
As shown in table 1, a phase II trial using a PIK3CA inhibitor, copanlisib in CCA, in first line setting in 
combination with cisplatin and gemcitabine is ongoing (NCT02631590) . 
• 7.3 BRAF 
BRAF mutations occur in a small portion of BTC patients; the most common mutation is V600E, whose 
frequency range from 5 to 8% [110]. 
In the study of Hyman the efficacy of vemurafenib was evaluated in non-melanoma cancers. In the cohort of 8 
CCA patients harboring BRAF V600E mutation, it was described one PR, which have persisted for more than 12 
months, four SD and three progression disease (PD) [111]. 
Furthermore, given the impressive activity noted in metastatic melanoma with BRAF V600 mutations using a 
combination of dabrafenib (BRAF inhibitor) and trametinib (MEK1 and MEK2 inhibitor), dual blockade merits 
evaluation also in this subset. A case report of a notable response in a IH-CCA patient who received this 
combination supports this hypothesis [112]. 
• 7.4 ROS, ALK, NTRK 
The presence of NTRK fusions in patients diagnosed with IH-CCA have been stated around 3.5% [113]. Sporadic 
fusions of ROS1 (up to 8.7%) and ALK (2.6%) are also described [114]. 
Compounds targeting an NTRK1/2/3, ROS1, or ALK gene rearrangement have demonstrated impressive ORR 
(57-86%) in a selected population of solid tumors [115]. 
Based on this data and the well-known clinical activity of ALK inhibitors in non-small cell lung cancer (NSCLC) 
with ALK or ROS1 translocation, a phase II trial is ongoing. This trial evaluates the efficacy and safety of ceritinib 
in patients with IH-CCA over-expressing ROS1 or ALK (NCT02374489). The recently identified FIG-ROS fusion 
suggests that crizotinib therapy merits evaluation: NCT02034981 is a phase II trial of crizotinib in patients 
harbouring an ALK, MET, or ROS1 alteration (Table 1). 
During the most recent ASCO annual meeting, the presentation of preliminary data on larotrectinib showed a 
consistent and durable antitumor activity of this drug in NTRK fusion cancers, across a wide range of tumor 
types. Among 55 NTRK fusion patients enrolled, 2 were CCA. The ORR for the 46 patients evaluated was 78%, 
with responses in 12 tumor types; no data on CCA were presented [116]. 
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• 7.5 FGFR 
FGFR pathway is involved in cellular migration, proliferation, survival, and differentiation. FGFR mutations and 
fusions predominate in IH-CCA in about 16% of cases [110]. In particular, genome-wide structural analyses 
showed numerous translocation events concerning the FGFR2 locus, ranging between 11 and 45% in IH-CCA 
patients [117]. The discovery of recurrent FGFR aberrations has opened a promising therapeutic avenue.  
BGJ 398, an oral FGFR inhibitor, is under evaluation in a phase II trial in advanced CCA with FGFR gene 
fusion/translocation after first-line chemotherapy (NCT02150967). The recent interim report of this trial was 
the following: 50 patients with BTC having FGFR genetic alterations were enrolled, the majority with IH-CCA. 
The ORR was 22% (all 8 patients with a partial response had an FGFR2 fusion) and the disease control rate 
(DCR) was 95% with PFS of 6 months [103].  
A number of other clinical trials involving selective FGFR small molecule inhibitors - including INCB54828 
(NCT02924376), BAY1163877 (NCT01976741), and the irreversible FGFR inhibitor TAS-120 (NCT02052778) - are 
currently in progress in early-phase trials in patients with advanced solid tumors, including BTC (Table 1). 
Moreover, nonselective multi-TKIs targeting also FGFR, including ponatinib and pazopanib, have showed some 
activity in patients with highly pretreated IH-CCA [117]. 
Finally, a nonselective TKI, ARQ 087 (NCT01752920), which inhibits RET, PDGF receptor, KIT, SRC, and FGFR1–3, 
is currently under evaluation in a phase II trial of patients with FGFR-aberrant tumors, including FGFR2 fusion–
positive advanced IH-CCA. Preliminary data from the phase I/II basket trial show that 3 of the 12 IH-CCA 
patients with FGFR2 fusion had a PR (DCR of 75%). 
In conclusion, the preliminary data for FGFR inhibitors in advanced IH-CCA are encouraging. 
• 7.6 IDH1-2 
IDH 1 and 2 mutations are frequent in IH-CCA (9 of 40, 23%), while lacking in EH-CCA and GBC patients. 
Additionally, results from several researches have shown that IDH1 mutation is more common than mutation 
of IDH2. 
Recently the findings of a dose escalation study of AG-120, an IDH1 inhibitor, in patients with advanced solid 
tumors having these mutations was presented by Burris et al. Of the 20 IH-CCA patients enrolled, 1 patient 
(5%) reached a PR and 11 patients (55%) had SD, with disease stability beyond 6 months [118]. 
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As shown in table 1, the potential efficacy of IDH1 and IDH2 inhibitors is currently being evaluated in clinical 
trials involving solid tumors such as BTC that harbor these mutations (NCT02481154, NCT02073994, 
NCT02381886).  
• 7.7 Immunotherapy 
Mechanisms involved in DNA repair are indispensable for the maintenance of genomic stability. Acquired or 
genetic mutations leading to defective DNA mismatch repair (MMR) are common in several tumors such as 
colorectal, gastric and endometrial cancer [110]. 
In the study of Jaivle et al regarding mutational profiling of BTC, mutations in genes involved in DNA repair - 
MSH6, BRCA1, BRCA2, ATM, MLH1 or MSH2 - was highly represented: 13% in IH-CCA, 26% in EH-CCA and 6% of 
GBC cases [103].  
Available data comes from KEYNOTE-028, an ongoing, phase 1b trial of pembrolizumab monotherapy for 
advanced solid tumors PD-L1-positive. Patients with PD-L1-positive BTC were included, with the exception of 
cancer of the ampulla of Vater. Of 89 BTC patients screened for PD-L1 expression, 42% were PD-L1-positive 
tumors. 24 pretreated patients - including 38% who received ≥3 prior therapies - were enrolled, showing an 
ORR (confirmed and unconfirmed) of 17%, with 4 PR, 4 SD, and 12 PD [119]. 
Given the demonstrated sensibility to programmed cell death protein 1 (PD-1) blockade with checkpoint 
inhibitor agents (e.g pembrolizumab or nivolumab), BTC patients presenting these mutations can represent a 
subset where immunotherapy may be effective. A number of immunotherapy studies are currently recruiting 
(Table 1). 
 
8-Conclusion  
Treatment for advanced BTC is challenging; although cisplatin and gemcitabine are considered the standard 1
st
 
line on the basis of a consolidated phase III study, survival outcomes remain dismal; TCR is achieved in 
approximately 80% of cases, but mOS is generally less than one year. Second-line treatment should be offered 
to patients who maintain a good PS, but no schedule should be preferred above the others. To date, there is no 
strong evidence to support the use of combination instead of single-agent therapy neither. Data from 
retrospective series show that 2
nd
 line treatment yields mPFS of 3 months and mOS of 7 months approximately. 
Moreover, treatment of BTC patients is encumbered with a high rate of complications, such as infections, need 
of biliary stenting, gastrointestinal toxicity, that have a high burden not only on patient’s care but also on social 
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and economical aspects. It goes without saying that every patient should be carefully evaluated for potential 
risks and benefit of active therapy and that every treatment, in addition to efficacy, should provide a 
manageable safety profile. 
In the past years, despite initial encouraging reports, targeted agents have failed to provide significant changes 
in the history of BTC patients. In particular, anti-EGFR and anti-VEGF treatment used in addition to cisplatin and 
gemcitabine as 1
st
 line treatment have provided no benefit in randomized control trials. Other targeted agents 
used, such as anti-MEK or anti-HER2, and data from some small non-randomized trials have shown little value 
and conflicting results. More recently, some other druggable targets are raising renewed interest in tailored 
medicine for BTC care. 
9-Expert opinion  
Despite a great effort to improve patients’ outcomes, in the past decades only few studies have provided 
practice-changing findings. The milestones of BTC care include the superiority of chemotherapy over BSC [12] 
and the identification of gemcitabine-cisplatin as standard treatment for advanced disease [10]. More recently, 
the role of adjuvant chemotherapy after resection of localized disease is being supported by randomized 
controlled trials [9]. These results have been achieved over a period of about 20 years and appear inadequate 
considering the progresses that have been made in other diseases, including gastrointestinal malignancies, in 
the same time span.  
Undoubtedly, dealing with a rare disease is the main disadvantage researchers have to face when designing 
clinical trials; in the 90ies BTCs were often grouped with ampullary and pancreatic cancers. The bulk of 
literature available includes small trials that, in spite of being multicentric, generally have a small sample size of 
40-100 patients. In addition, some of the first studies with targeted therapies were not supported by a strong 
rationale or an accurate patient selection; in some cases, researchers have tried to apply the same paradigms 
that showed success in other cancer types to BTC, an orphan disease with very few options. 
We have already pointed out that the different entities that are commonly included in BTC, such as IH-CCA, EH-
CCA e GBC, have also different clinical and molecular features. Sometimes they are used as stratification factors 
for randomization or to conduct subgroup analyses. In our opinion, this issue is a great limitation especially for 
studies with targeted agents because the different pathways activated or inhibited are strongly influenced by 
the molecular features of the tumor, which vary strongly among the entities. For example, in the first studies 
with anti-EGFR therapies, slightly better results were observed in the IH-CCA groups, but their real impact was 
never significant because of the small sample size or the retrospective character of the analyses. 
With the advent of new, advanced technologies like next-generation sequencing the underpinnings of genomic 
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landscape of BTCs are being disclosed. To date, no distinct molecular mutation characterizes BTCs, but the 
scenario is scattered into several alterations that have a relatively low rate, especially if we consider the 
different anatomical locations. Among the druggable alterations, IDH1-2 mutations and FGFR translocations are 
those that show the most potential because of higher frequency and the investigation of different compounds 
in clinics. 
In parallel with the progress of technologies, drug development in the past few years is substantially changing; 
trial design is moving from the standard approach from phase I to phase III trials and approval, to newest 
methods. More often we are observing proof-of-concept studies that lead to an accelerated approval by 
regulatory agencies, thanks to striking results on a limited number of patients in non-randomized phase I or II 
trials.  
Moreover, revolutionary trials designs permit to handle multiple related questions with fewer patients. In 
basket trials the effect of one drug is tested at the same time but in a variety of tumor types that share the 
same single mutation. Umbrella trials indeed have many different treatment arms within one trial; people are 
assigned to a particular treatment arm of the trial based on their type of cancer and the specific molecular 
makeup of their disease.  
Nivolumab and pembrolizumab have recently been granted FDA approval for microsatellite instability-high 
(MSI-H) tumors; this is the first time a cancer treatment to be approved based on a common biomarker rather 
than tumor type. A percentage of BTCs patients are potentially involved by this progress: similarly, some 
ongoing basket trials that we have introduced in the previous paragraphs, such as those directed against ROS, 
ALK, NTRK1/2/3 are deemed to provide interesting results for patients harboring low-frequency mutations. 
Thanks to these new approaches and to the better knowledge of potentially actionable genomic alterations in 
BTCs it will be possible to offer a chance for tailored medicine to BTCs patients ant to and to meet an unmet 
clinical need. 
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Table 1 New therapies under evaluation in biliary tract cancers  
 
 
Therapeutic 
regimen 
 
Target Phase  
 
ClinicalTrials.gov 
identifier  
Status 
VEGF and multitarget 
 
Ramucirumab  VEGFR2 2  2  NCT02520141  Recruiting 
GEMCIS and 
ramucirumab or 
merestinib  
VEGFR2 c-MET  2 NCT02711553  
 
Active (not 
recruiting) 
FOLFOX and 
cediranib  
 
VEGFR 2 NCT01229111  Not recruiting 
(results expected) 
Regorafenib  VEGFR1-3, c-KIT, 
TIE-2, PDGFR-β,  
C-Raf, B-Raf, p38 
MAPK, FGFR1-2, 
Ret 2  
2 
 
2 
NCT02115542  
 
NCT02053376  
Active (not 
recruiting) 
Active (not 
recruiting) 
 
Apatinib  VEGFR-2 2 NCT03144856 Recruiting 
Lenvatinib 
 
VEGFR-2, VGFR-3 2 NCT02579616 Active (not 
recruiting) 
Varlitinib + GEMCIS EGFR 2 NCT02992340 
 
Recruiting 
MAPK 
Trametinib versus 
CAP/5FU  
MEK 1/2  2 NCT02042443  Not recruiting 
(results expected) 
Binimetinib 
(MEK162) and 
GEMCIS  
MEK 1/2 2 NCT01828034  
 
Active (not 
recruiting) 
Selumetinib (at 
different doses) 
and GEMCIS  
 
MEK 1/2  2 NCT02151084  Recruiting 
HER 2 
Afatinib HER2 1/1b NCT02451553 Recruiting 
Trastuzumab 
Emtansine 
HER2 2 NCT02999672 Recruiting 
Neratinib HER2 2 NCT01953926 Recruiting 
Other     
Copanlisib + 
GEMCIS 
PIK3CA 2 NCT02631590 
 
Recruiting 
Entrectinib NTRK1/2/3, ROS1, 
ALK 
2 NCT02568267 
 
Recruiting 
Larotrectinib NTRK1/2/3 2 NCT02576431 
 
Recruiting 
LDK378 ALK, ROS1 2 NCT02374489 Recruiting 
Crizotinib ALK, MET, ROS1 2 NCT02034981 Recruiting 
Immunotherapy 
Pembrolizumab PD1 2 NCT03260712 Recruiting 
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Cisplatine 
Gemcitabine 
Nivolumab  
 
PD1  2 NCT02829918  Recruiting 
Pembrolizumab 
and GM-CSF  
 
PD1  2 NCT02703714  Recruiting 
Ipilimumab and 
nivolumab  
CTLA4 and PD1  2 NCT02923934  Recruiting 
 
Pembrolizumab + 
CAPOX 
PD1 2 NCT03111732 Recruiting 
Infigratinib FGFR2 2 NCT02150967 Recruiting 
INCB054828 FGFR2 2 NCT02924376 Recruiting 
BAY1163877 Pan-FGFR 1 NCT01976741 Recruiting 
TAS-120 FGFR  NCT02052778 Recruiting 
ARQ 087 FGFR1–3, RET, 
PDGFR, KIT 
1/2 NCT01752920 Not recruiting 
(results expected) 
AG881 IDH1-2 1 NCT02481154 Active (not 
recruiting) 
AG-120 IDH1 1 NCT02073994 Active (not 
recruiting) 
IDH305 IDH1 1 NCT02381886 Suspended 
Multiagent 
Multiple arms 
based on molecular 
profiling 
(cetuximab, 
trastuzumab, 
gefitinib, lapatinib, 
everolimus, 
sorafenib, 
crizotinib)  
Multiple (EGFR, 
HER2, mTOR, 
VEGF/EGFR/ 
PDGFR, ALK/ROS1)  
2 NCT02836847  
 
Recruiting 
Sulfatinib VEGFR 1,2,3, FGFR 
1, CSF1R 
 
2 NCT02966821 
 
Recruiting 
Regorafenib + 
modified GEMOX 
VEGFR1-3, c-KIT, 
TIE-2, PDGFR-β,  
C-Raf, B-Raf, p38 
MAPK, FGFR1-2, 
Ret 2  
2 NCT02386397 
 
Recruiting 
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2-HG 2-Hydroxyglutarate 
5-FU 5-Fluorouracil  
αKG α-Ketoglutarate  
ARAFm ARAF Mutation  
α-SMA α-Smooth Muscle Actin  
BSC Best Supportive Care  
BTC Biliary Tract Cancer 
CaM Cancer Associated Macrophages  
CAF Cancer Associated Fibroblasts   
CCA Cholangiocarcinoma  
CK Cytokeratin  
c-KIT Stem Cell Growth Factor Receptor 
CR Complete Response 
DCCA Distal Cholangiocarcinoma 
DCR Disease Control Rate 
ECOG Eastern Cooperative Oncology Group  
EGFR Epidermal Growth Factor Receptor  
EH-CCA Extrahepatic Cholangiocarcinoma 
EMT Epithelian- Mesenchymal Transition  
FGFR Fibroblast Growth Factor Receptor 
FIG-ROS Fused In Glioblastoma c-ROS Oncogene 1  
FOLFIRI 5- Fluorouracil/Leucovorina- Irinotecan  
FOLFOX 5- Fluorouracil/Leucovorina- Oxaliplatin  
GBC Gallbladder Cancer  
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GEMOX Gemcitabine- Oxaliplatin  
HCC Hepatocellular Carcinoma 
HER-2 Human Epidermal Growth Factor Receptor 2  
HGF Hepatocyte Growth Factor  
Hh Hedgehog  
IDH1 Isocitrate Dehydrogenase 1  
IDH2 Isocitrate Dehydrogenase 2 
IH-CCA Intrahepatic Cholangiocarcinoma 
mAbs Monoclonal Antibodies  
MAPK Mitogen Activated Proteine Kinases  
mGEMOX Modified Gemcitabine- Oxaliplatin  
MMR Mismatch Repair  
mOS Median Overall Survival 
mPFS Median Progression Free Survival  
MSI-H Microsatellite Instability-High  
mTOR  Mammalian Target of Rapamycin 
NSCLC Non- Small Cell Lung Cancer   
ORR Overall Response Rate 
OS Overall Survival  
PCCA Perihilar Cholangiocarcinoma  
PD Progression Disease  
PD-1 Programmed Cell Death Protein 1  
PDGF Platelet-Derived Growth Factor 
PD-L1 Programmed Cell Death- Ligand 1 
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PFS Progression Free Survival 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
PKB Protein Kinase B 
PR Partial Response 
PS Performance Status  
PSC Primary Sclerosing Cholangitis  
PTEN Phosphatase and Tensin Homolog 
QoL Quality of Life  
RET Rearranged During Transfection  
RR Response Rates  
SD Stable Disease 
SDF-1 Stromal Cell Derived Factor 1  
STAT3 Signal Transducer and Activator of Transcription 3  
TCR Tumor Control Rate  
TGF-β Transforming Growth Factor β  
TKIs Tyrosine Kinase Inhibitors  
TRAIL Tumor Necrosis Factor Related Apoptosis Inducing Ligand  
VEGF Vascular Endothelial Growth Factor 
WISP1 Wnt Inducible Signaling Protein-1v  
WT Wild Type 
XELIRI Capecitabine- Irinotecan 
XELOX Capecitabine- Oxaliplatin 
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 1 
Title 
Emerging molecular target antagonists for the treatment of biliary tract cancer 
 
Abstract  
Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence 
but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of 
effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is 
cisplatin/gemcitabine combination, whereas no standard in 2
nd
-line has been defined. Hence, the current goal 
is to better understand the biology of BTCs, discovering new treatment methods and improving clinical 
outcomes. 
Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular 
signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical 
trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. 
Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. 
Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be 
reviewed. 
Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted 
treatments under evaluation. In addition, revolutionary innovative trial design will allow to offer a chance for 
tailored medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their 
histology. 
 
Manuscript 
1-Background  
Biliary tract cancer (BTC) is a heterogeneous group of tumors arising from the epithelial lining of the biliary 
tree. The classification is based according to the anatomical location; BTC includes gallbladder cancer (GBC) and   
cholangiocarcinoma (CCA); the latter is further divided into intrahepatic (IH-CCA), and extrahepatic (EH-CCA), 
which includes EH-CCA perihilar (PCCA) and distal CCA (DCCA). IH-CCAs arise above the second order bile ducts, 
whereas PCCAs are located between the insertion of the cystic duct and the second order bile ducts, and 
DCCAs are located below the insertion of the cystic duct [1, 2]. 
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 2 
Even though GBC, intrahepatic, perihilar and distal extrahepatic CCA are grouped as BTCs, their clinical 
presentation, pathobiology and management are different, and they should be viewed as separate entities. 
Despite being considered an infrequent cancer in the Western world, with an incidence of 1-2 cases every 
100,000 inhabitants, BTCs are extremely common in South America and in some areas of Asia, with up to 96 
cases/100,000 [3]. 
Histologically, more than 95% of BTCs are adenocarcinomas, often poorly differentiated. About 10% of EH-CCA 
are well differentiated papillary cancers, but mucinous (5%) and squamous cancers (2%) are also described [4]. 
Several classifications have been proposed for IH-CCA owing to its highly heterogeneity. The two main 
histological subtypes are bile ductular type (mixed), arising from small intrahepatic bile ducts, and bile duct 
type (mucinous), arising from large intrahepatic bile ducts. These differences are also reflected in different 
molecular characteristics [5]. Notably, bile ductular type IH-CCAs share clinicopathological similarities with 
cytokeratin (CK) 19-positive hepatocellular carcinoma (HCC), and the bile duct type IH-CCAs share phenotypic 
traits with PCCA and pancreatic cancers [6]. 
Beyond the differences, BTC have common features, such as a highly desmoplastic reaction, rich tumor 
microenvironment, and profound genetic heterogeneity, all contributing to the development of drug resistance 
and almost complete absence of curative therapies for metastatic disease. 
The vast majority of BTC (70%) occurs sporadically. Nevertheless, several pathologic conditions have been 
determined as possible risk factors such as Primary Sclerosing Cholangitis (PSC), choledochal cysts, parasitic 
infestation, and viral hepatitis B and C. Potential risk factors with less evidence are diabetes, alcohol, smoking, 
obesity and specific genetic polymorphisms [7]. Therefore, although a single trigger cannot be identified, 
different environmental, genetic and social factors may be rather involved and justify heterogeneous 
geographic distribution. 
 
Most patients with early stage disease are asymptomatic and diagnosing BTC at an early stage remains a 
challenge owing to its ‘silent’ clinical presentation, difficult to access anatomical location, and highly 
desmoplastic, paucicellular nature, which limits the sensitivity of cytological and pathological diagnostic 
approaches.  
Surgery is the preferred treatment option for localized BTC, but only a minority of patients (approximately 
35%) has early stage disease that is amenable to surgical resection with a curative intent. Survival after radical 
surgery generally depends on margin status (negative-R0 or positive-R1-R2 status), vascular invasion and lymph 
node involvement. Even after R0 resection 3-years survival rate is approximately 40-60%, and it can be lower in 
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 3 
case of lymph node positivity [8]. 
The unfavorable prognosis of recurrent disease drove efforts to lower the rate of relapse through 
postoperative adjuvant therapy. So far, the great part of the available literature was made of retrospective, 
non-randomized studies and meta-analyses: the majority took in consideration heterogeneous populations of 
patients, treated with different systemic drugs with or without radiotherapy. Recently, following the 
presentation of the preliminary results of the BILCAP study, a standard of care for adjuvant treatment is 
available. In this randomized phase III trial, postoperative capecitabine was compared to surveillance: the 
primary endpoint of the study was formally not met, despite a difference of 15 months in the median overall 
survival (mOS) estimated values (51 versus 36 months, p = 0.097). However, mOS was significantly higher in the 
chemotherapy arm both after sensitivity analyses and in the per protocol analysis [9]. 
For patients with advanced-stage or unresectable disease, the available systemic therapies are of limited 
effectiveness: the mOS with the current standard-of-care regimen (gemcitabine and cisplatin) is <1 year [10] 
and a probability to outlive 5 years is about 5% [11]. 
 
2-Medical need 
Randomized trials have shown that systemic chemotherapy increases survival and improves quality of life (QoL) 
in patients with metastatic BTC as compared with best supportive care (BSC). In the study by Glimelius, 90 
patients with metastatic or locally advanced pancreatic carcinoma or BTC have been randomly assigned to 5-
fluorouracil (5-FU) -based chemotherapy or BSC. A clear benefit of chemotherapy on both mOS (6 vs 2.5 
months in BSC group p< 0.01) and QoL was demonstrated [12]. More recently, modified gemcitabine and 
oxaliplatin (mGEMOX) proved a significant improvement in mOS not only over BSC, but also over 5-FU/folinic 
acid in unresectable GBC (9.5, 4.6 and 4.5 months respectively)[13]. 
The majority of trials in the metastatic setting were performed with fluoropyrimidine or gemcitabine 
monotherapy or in combination with other cytotoxic agents. 5-FU as single agent yields a variable response 
rates (RR) from 10% to 40%. The combination of 5FU with other drugs (etoposide, interferon, cisplatin and 
oxaliplatin) has proved moderate efficacy, limited overall survival (OS) benefit, and a significantly greater 
toxicity profile. Since the late 90s, the adoption of gemcitabine as the standard of care for patients with 
pancreatic cancer led to interest in its use for hepatobiliary tumors. As a single agent, gemcitabine has shown 
RRs ranging from 0% to 30%, whereas its association with other agents has determined advantages in survival 
and RRs (up to 41%) [14]. In 2007 a pooled analysis of 104 trials in advanced BTC, demonstrated the superiority 
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 4 
of combination therapy compared to monotherapy in RR and tumor-control-rate (TCR). Subgroup analysis also 
underlined that gemcitabine and platinum association had significantly higher response and TCRs compared to 
fluoropyrimidine/gemcitabine monotherapy or fluoropyrimidine plus platinum regimens [15]. 
Suggestions from this meta-analysis were turned into a standard of care by Valle’s Phase III ABC- 02 trial. Four 
hundred and ten patients with locally advanced or metastatic CCA, GBC and ampullary carcinoma were 
randomly assigned to receive gemcitabine alone (1000 mg/m2 days 1, 8, 15 q 28) vs gemcitabine and cisplatin 
(1000 mg/m2 + 25 mg/m2 days 1, 8 q 21) for up to 24 weeks of treatment. After a median follow-up of 8.2 
months, mOS, that was the primary endpoint of the study, was statistically improved in the combination arm 
(11.7 vs. 8.1 months; p < 0.001). The benefit was preserved across the subgroups according to primary tumor 
site, median progression-free-survival (mPFS) was improved (8.0 months vs. 5.0 months; p < 0.001), without 
significant increase in toxicity. [10]. Following the results of this trial, a definite standard regimen for a disease 
that has been “orphaned” for too long, was finally provided. Equivalent results have been replicated in the 
japanese population [16]. Other combination schemes have also been evaluated as first line treatment in phase 
II trials [17-19]. Among these, gemcitabine and oxaliplatin (GEMOX) is widely used in clinical practice for its 
good response rate and favorable toxicity profile, although a direct comparison with the standard of care is 
lacking [13, 20]. 
Following a meta-analysis of the English and Japanese randomized trials, single agent gemcitabine is a 
recommended option only for patients with Performance Status (PS) 2 according to Eastern Cooperative 
Oncology Group (ECOG) scale [21].  
After the failure of the 1
st
 line therapy, approximately half of the patients still have a good PS and satisfactory 
organ function [22], but the advantages of 2
nd 
line therapy are still unclear. In a large retrospective analysis, 196 
patients who received 2nd line treatment after gemcitabine and cisplatin/oxaliplatin, were analyzed. The most 
common regimens used were 5-FU/folinic acid, FOLFIRI, XELIRI, FOLFOX, XELOX, 5-FU and cisplatin: globally, 
the outcome was poor, the mPFS and OS being 3.2 and 6.7 months, respectively, and no chemotherapy 
regimen proved superiority over the others [23]. In another Italian retrospective analysis, PS emerged as the 
most important prognostic factor to select the patients that may benefit from 2
nd
 line treatment [24]. 
 
3-Existing treatment  
In the past decade we have entered the era of targeted therapies: this strategy has modified the therapeutic 
approach of many cancers but the first attempts of using targeted treatments in BTCs have been so far 
unsatisfactory. Here, we revise the first studies that have explored targeted therapies in BTC.  
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 5 
• 3.1 EGFR family pathway 
Epidermal growth factor receptor (EGFR) is mutated and overexpressed in cancer human samples. EGFR is 
extensively represented in BTC, being expressed in 100% of IH-CCAs, 52.6% of EH-CCAs, and 38.5% of GBCs. 
[25]. Mutations have been found in up to 15% of BTCs [26, 27]. EGFR activation triggers the Mitogen Activated 
Proteine Kinases (MAPK)–ERK pathway, an oncogenic signalling pathway in cancer: it donates a proliferative 
advantage to cancer cell, contributes to progression through epithelian-mesenchymal transition (EMT) and 
leads to a poor clinical outcome [28, 29]. In preclinical studies, EGFR inhibitors tested in combination with 
chemotherapy have shown promising activity, providing a strong preclinical rationale for anti-EGFR therapy in 
BTC. Different strategies targeting EGFR have been studied such as tyrosine kinase inhibitors (TKIs) or 
monoclonal antibodies (mAbs) alone or in association with chemotherapy. 
Erlotinib, a selective, reversible, orally-active EGFR inhibitor, after promising results in several phase II studies, 
failed to confirm its superiority in OS in a large phase III study. Compared to the combination of GEMOX, the 
addition of erlotinib in patients with newly diagnosed metastatic BTC significantly increased RR (40% vs 21%; 
p=0.005) but mPFS and OS were not increased (4.2 vs 5.8 months p=0.087 and 9.5 months in both arms, 
p=0.611 respectively). Subgroup analyses showed that in patients with CCA the addition of erlotinib prolonged 
mPFS (5.9 months vs 3.0 months; HR 0.73, 95% CI 0.53–1.00; p=0.049) [30]. 
Cetuximab is a mAb targeting EGFR, evaluated in combination with chemotherapy in BTC in several phase II 
trials. In a phase II study of cetuximab in combination with GEMOX, the treatment achieved a mPFS of 8.3 
months and OS of 12.7 months, with high RR [31]. Following randomized trials failed to demonstrate a 
significant benefit of the GEMOX and cetuximab combination. In the BINGO study, cetuximab was tested in the 
1
st
 line setting in addition to GEMOX vs GEMOX alone. Despite being well tolerated, cetuximab did not 
significantly improve outcomes: mPFS was 6.1 months with cetuximab and 5.5 months without cetuximab, 
while mOS was 11.0 months with cetuximab and 12.4 months without cetuximab [32]. In a similar study in the 
Asiatic population, mPFS was 6.7 months with cetuximab and 4.1 months without cetuximab (p = 0.05), while 
mOS was 10.6 months vs 9.8 months respectively (p = 0.91). KRAS mutations, that are a well-known negative 
predictive factor of response to anti-EGFR mAbs, were identified in 36% of tumors, and did not affect the 
overall response rate (ORR) or mPFS [33]. 
Panitumumab, a fully human antibody against EGFR, has been tested in combination with chemotherapy in 
non-randomized and randomized, phase II trials. In particular, in the Vecti-BIL trial advanced BTC patients were 
selected upfront for KRAS mutational status. The study revealed that the addition of panitumumab to GEMOX 
compared to GEMOX alone did not significantly improve mPFS, (5.3 months in experimental arm vs 4.4 months 
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 6 
in control arm), neither OS (10.2 months in experimental arm vs 9.9 months in control arm) in KRAS wild type 
(WT) BTC patients [34].  
Despite the results of a recent meta-analysis suggesting a potential role of anti-EGFR therapy in prolonging PFS 
and RR, the current evidence does not support its use in BTC [35]. 
• 3.2 MEK pathway 
Targeting the RAS/RAF/MEK/ERK pathway, a major player in the cellular processes, including proliferation and 
apoptosis, is thought to be a winning strategy in many cancers including BTC.  
The second-generation, uncompetitive inhibitor of MEK 1/2 - selumetinib - was investigated in a phase II study 
of 28 advanced BTC patients. Median PFS was 3.7 months and the mOS was 9.8 months, with a 12% of ORR 
[52]. Recently a Phase Ib trial has tested the pharmacokinetics and toxicity profile of selumetinib in 
combination to cisplatin and gemcitabine. Other trials are needed to demonstrate its applicability in clinical 
practice [53]. 
Another uncompetitive inhibitor of MEK 1/2, binimetinib, after encouraging results in safety and activity during 
phase I studies [54], is currently under evaluation in phase II studies (NCT02151084, NCT01828034). 
Recently, the open-label, multicentre, single-arm trial, evaluating pazopanib - an orally available multikinase 
inhibitor of VEGF (vascular endothelial growth factor) receptor, PDGF (platelet-derived growth factor) receptor, 
c-KIT (stem-cell growth factor receptor), fibroblast growth factor receptor (FGFR) and RAF - in addition to 
trametinib - an orally available highly specific inhibitor of MEK 1 and MEK 2 - showed discouraging results. 
Despite the trend towards increased 4-month PFS, the difference did not reach statistical significance. The mOS 
was 6.4 months (95% CI: 4.3–10.2) and the ORR was 5% (95% CI: 0.13–24.9%) [55]. 
• 3.3 VEGF 
The vVascular endothelial growth factor (VEGF) pathway promotes tumor growth - by angiogenesis and 
vascular permeability - in several tumors including BTC [36]. In CCA, VEGF expression is reported in about 30-
40% of cases and is correlated with lymphnode metastasis and poor prognosis [37, 38]. VEGF expression is 
reported in 50% of GBC and also in this sub-group a poor prognosis is observed [39]. Based on preclinical and 
clinical data supporting a VEGF-targeted approach, several studies have evaluated the effectiveness and 
applicability of targeted therapy (bevacizumab, sorafenib, cediranib, vandtetanib) in metastatic BTC, providing 
only limited information, principally because of their phase II design. Therefore, the role of antiangiogentic 
agents in the treatment of BTC is not well defined. 
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Bevacizumab is a recombinant humanized mAb whose efficacy has been tested in patients affected by 
advanced BTC. In two studies it was tested in combination with erlotinib and in sequence with gemcitabine and 
oxaliplatin, without favorable results [40, 41]. More recently, a small phase II study evaluated the combination 
of gemcitabine, capecitabine, and bevacizumab in a first-line setting, showing a mPFS and mOS similar to those 
observed with standard chemotherapy (8.1 months and 11.3 months, respectively) [42]. Larsen et al. recently 
presented the results of a phase II trial of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-
line setting in 50 BTC patients. Median PFS was 3.6 months and mOS was 6.4 months [43]. To date, the role of 
bevacizumab on BTC has been evaluated only in single-arm studies, with no randomized study performed. 
Cediranib is a potent inhibitor of the VEGF receptor tyrosine kinases -also directed against PDGF receptors and 
c-KIT being investigated in a recent phase II study [44]. Patients were randomized to receive cisplatin and 
gemcitabine plus either cediranib or placebo. Cediranib did not significantly improved mPFS (7.7 months in the 
cediranib arm vs. 7.4 months in the placebo arm). There was a trend towards longer OS in the experimental 
arm compared to placebo (14.1 vs 11.9 months, respectively) [45]. 
For definitive conclusions, we will have to wait for the results of the ongoing phase II trial, investigating 
cediranib in combination with modified FOLFOX6 in advanced BTC (NCT01229111). 
Sorafenib is an oral multikinase inhibitor directed against VEGF receptors and PDGF receptor-β, and blocking 
downstream intracellular serine/threonine kinases, like Raf-1, WT and mutant B-Raf. 
After the defeats in monotherapy in several studies, the more recent conducted by Luo et al [46], Sorafenib 
was evaluated in combination with standard chemotherapy. 
First, Moehler et al. investigated Sorafenib in the first line setting, treating patients with gemcitabine with 
either sorafenib or placebo. In this study, longer mPFS and OS were found in the gemcitabine plus placebo arm 
[47]. Then, a randomized, double-blinded, multicenter phase II trial investigating a combination of gemcitabine, 
cisplatin with either sorafenib or placebo demonstrated no significant difference in mPFS and mOS between 
the two arms [48]. Finally, a small trial conducted by Lee et al. showed that the addition of sorafenib to 
gemcitabine and cisplatin did not improve efficacy over historical data, but there was an increase of toxicity 
[49]. 
Sunitinib is another oral small molecular-targeted drug inhibiting several intracellular and receptor protein 
kinases, including VEGF and PDGF receptors, c-KIT, and rearranged during transfection (RET). In the only 
available phase II study, the role of sunitinib was investigated as a second-line treatment in advanced BTC 
demonstrating only marginal efficacy; ORR was 8.9 % and mPFS was 1.7 months [50]. 
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Vandetanib is an orally active, multikinase inhibitor targeting VEGF receptor 2, EGFR and RET kinase. In the 
Italian "VanGogh" study, 165 BTC patients chemotherapy-naive were randomized into three groups: 
vandetanib monotherapy, vandetanib plus gemcitabine and gemcitabine plus placebo. Median PFS was 105 
days (95 % CI 72–155), 114 days (95 % CI 91–193), and 148 days (95 % CI 71–225) respectively, while mOS was 
228 days (95 % CI 190–364), 284 days (95 % CI 213–359), and 307 days (95 % CI 254–523) for the three arms 
respectively. Thus, vandetanib alone or in association with gemcitabine did not demonstrate any superiority 
when compared with gemcitabine alone [51]. 
In conclusion, the role of VEGF inhibition in addition to chemotherapy for patients with advanced BTCs remains 
still investigational, but increasingly burdened by the absence of a biomarker of efficacy for VEGF inhibitors. 
 
4-Market review 
Throughout the therapeutic course of BTC patients, complications are a constant. Infections, sepsis and 
cholangitis often undermine patients’ health. Furthermore, chemotherapy is associated with high rate of side 
effects that requires spending of many economic resources.  
We have considered two cost-effectiveness analysis conducted in USA and Japan. They evaluate cost-
effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with 
gemcitabine alone. These studies get to different conclusion, probably for different conditions in each 
nationDespite being two comparable analyses in different populations, their conclusions are opposite;. Indeed, 
Roth et al. demonstrated that cisplatin and gemcitabine combination was a cost-effective alternative to 
gemcitabine monotherapy. However, Tsukiyama et al., on the contrary, suggested that gemcitabine 
monotherapy was a better treatment strategy for advanced BTC. These different conclusions may be due to 
varying health care conditions and  probably because of different long-term palliative care cost in Japan than in 
the USAbetween the countries. 
Surprisingly, in both studies the majority of the resources were employed for supportive and palliative care 
rather than for drugs [56, 57]. 
For these reasons, systemic treatments are required not only to prolong survival, but also to limit palliative 
interventions. Recently, immunotherapy and target therapies have demonstrated to increase QoL and to be 
associated to lower rates of side effects in several cancer types as compared to chemotherapy [58-60]. For 
these reasons, alternative treatment strategies are also strongly encouraged in BTC patients. 
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5-Current research goals 
Carcinogenesis is a multistep process encountering imbalance between proliferative and inhibitory stimuli, 
dysregulation of apoptotic signals and abnormal response to angiogenetic factors which are responsible for 
invasion and metastatization events [61]. It involves specific cell genome derangements that contribute to the 
selective growth advantage of cancer. Specific pathways govern cell fate through proliferation, cell survival, 
differentiation, epigenetic changes and maintenance of genome integrity [62]. 
The genomic heterogeneity of BTC is well-known. As previously discussed, it’s not only related to the diverse 
anatomical location of the tumor but also to etiology, the various risk factors and associated pathologies. 
Interestingly, mutations in TP53 responsible for genome integrity are very common in all subgroup of BTC but 
are more often observed in liver-fluke related CCA [63]. These differences will need to be considered when 
assessing outcome and in devising therapeutic strategies for CCA and GBC [2, 61, 64-67]. Advances in genome-
wide technologies have made feasible the discovery of other possible targetable or actionable molecular 
alterations in BTC. Precision therapy for this group of tumors is subordinated to an enhanced understanding of 
genetic and molecular alteration for each subtype. 
 
6-Scientific rationale and molecular pathogenesis  
• 6.1 Proliferation and cell survival.  
Several growth pathways are implicated in arising and progression of BTCs. Here we revise the most promising 
preclinical evidences that could, in the near future, have a clinical counterpart. 
ErbB family, that includes four different receptors (ErbB1 or EGFR, ErbB2 or HER-2/neu, ErbB3 and ErbB4 ), 
have a main role in carcinogenesis processes and represents the most extensively mutated pathway of the GBC 
samples [68]. We have already introduced the role of EGFR and its clinical implications. 
Human epidermal growth factor receptor 2 (HER2) amplification has been observed in BTCs patients with a 
prevalence in EH-CCA (about 20%), GBC (9.8%) and a rare incidence in IH-CCA. The prognostic meaning of HER2 
has not yet been completely clarified but could become a relevant predictive factor [68, 69]. 
KRAS mutations occur in BTC and the reported incidence is 7-47%. It is usually associated with the alteration of 
other factors, such as EGFR, HER2 or MET [68, 70]. A recent work showed poor prognosis for KRAS mutated 
CCA that is more pronounced in the subgroup with transcriptional enrichment of genes that regulate 
proteasome activity [71]. 
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Some studies reported BRAF mutations in a percentage between 0% and 22%. In a large cohort, BRAF V600E 
mutation was observed in 5.9% of GBC, 3% of IH-CCA and 0% of EH-CCA and no clear correlation with prognosis 
was detected [72, 73]. 
Recently, ARAF mutation (ARAFm), a member of the RAS family, has been reported in 11% of IH-CCA iCCA. 
ARAFm leads to an increased basal and inducible activity when compared to WT protein. Further studies need 
to investigate the oncogenic potential of this new target. [74]. 
ROS1 fusion proteins have been recently implicated in CCA carcinogenesis. The fused-in-glioblastoma-c-ros-
oncogene 1 (FIG-ROS) was found in 14-16% of EH-CCA [75] and it mediated cancerogenesis in KRAS dependent 
mode with a high aggressiveness [76]. 
The expression level of hepatocyte growth factor (HGF) receptor (also known as c-Met) is amplificated either in 
CCA and GBC. Miyamoto analyzed 247 patients and noted MET high expression in 11.7% of IH-CCA and 16.2% 
in EH-CCA. MET seems to play a central role in carcinogenesis through the protection from apoptosis and 
promoting angiogenesis and tumor invasion. In CCA it is associated with EGFR expression and represents a poor 
prognostic factor. Moreover, it could be linked to acquired resistance to EGFR or HER2 inhibitors [77, 78]. 
FGFR is a tyrosine kinase receptor involved in numerous cellular process including proliferation, angiogenesis 
and tissue repair. Disruption of this pathway has been implicated as driver event in biliary cancer formation. 
Fusions of FGFR gene have been reported in some cancer type; in BTC several gene fusions have been 
described, the most frequent being FGFR2-BICC1 fusion. This new protein seems to have a higher incidence in 
female and a link with hepatitis infection. It is constitutively active and leading to the activation of MAPK and 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/ mammalian target of 
rapamycin (mTOR) pathways. Moreover, FGFR translocation may confer a survival benefit. Indeed, in a western 
dataset a superior cancer specific survival was observed in patients with FGFR2 translocation compared to non 
translocated patients (123 months vs 37 months) [65, 74, 79].  
Aberration in tumor suppressive gene phosphatase and tensin homolog (PTEN) has been correlated with 
clinical outcome. Indeed, PTEN loss has been associated with poor outcome in all BTC, particularly in 
combination with either activated Protein kinase B (PKB), also known as Akt or mTOR. However, genetic 
alteration in AKT genes, with normal level of PTEN, were associated with cancerogenesis but also with 
favorable prognosis. These findings suggest isolated AKT alteration could have an important role in the 
initiation of IH-CCA but not in progression of this subgroup [80-82]. 
Different pathways have been implicated in carcinogenesis and proliferative advantage in CCA. However, these 
pathways overlap in several points, providing a molecular reason for resistance to target therapies.  
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Besides, not every cancer has a proliferative signature. Sia et al., using an integrative molecular analysis 
technique, have identified gene signatures in IH-CCA and have correlated them with pathological features and 
clinical patients’ outcome. The authors describe two categories of IH-CCA: a proliferative class and an 
inflammatory class. The proliferative class, that accounts for 62% of cases, was typified by alterations in several 
oncogenes included in RAS-RAF-MEK-ERK or PIK3CA-AKT-mTOR signaling pathway, implicated in cell 
proliferation and cell survival, respectively.  
The inflammatory class showed activation of inflammatory pathways, overexpression of cytokines (i.e. IL-6) and 
signal transducer and activator of transcription 3 (STAT3). STAT3 is a mediator that modulates cell growth and 
survival while IL-6 is an inflammatory cytokine produces either by CCAs and cholangiocytes stimulated by an 
inflammatory noxa. IL-6 is involved in cell survival through upregulation of Mcl-1 via AKT-dependent 
mechanism. Mcl-1 mediates tumor necrosis factor-related apoptosis inducing ligand (TRAIL) resistance and cell 
survival. IL-6 is also implicated in upregulation of Mcl-1 through a STAT3 dependent mechanism [83, 84].  
• 6.2 Cell differentiation. 
The Notch signaling pathway has a main role in cell differentiation, inflammation and carcinogenesis. Notch 
activation was implicated in de-differentiation of adult hepatocytes into precursors of IH-CCA. These studies 
not only show the high plasticity of liver cell but also change the traditional model according to which CCA cells 
derived from cholangiocytes or hepatic common progenitor cells [85]. These observations could be combined 
to Sia et al. data. In this work, the authors describe how gene signatures, especially the proliferation class 
one's, overlap with those identified in HCC. These data provides us a second model of CCA carcinogenesis; not 
only based on alteration of epithelial cells of biliary tree but also on de-differentiation of adult 
hepatocytes.[84].  
• 6.3 Epigenetic changes. 
Tumor cells may also acquire an advantage in survival and proliferation through epigenetic changes that lead to 
silencing of onco-suppressor genes. Mutations of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are among 
the most common genetic alteration in IH-CCA (14-36%) [70, 86], with unclear prognostic significance [87]. No 
mutations in these genes were observed in EH-CCA and GBC. Mutant IDH proteins lead to an abnormal 
enzymatic activity inducing to production of 2-hydroxyglutarate (2-HG) from α-ketoglutarate (αKG), which is 
considered an oncometabolite and causes epigenetic changes. Furthermore, deficiency in αKG inhibits activity 
of αKG-dependent dioxygenase and results in altered cell differentiation, survival and extracellular matrix 
maturation [88, 89]. Mutant IDH blocks liver progenitor cells that, as a result of altered hepatocyte response to 
hepatic injury, could lead to the development of malignant lesions. Indeed, a recent work has shown that 
mutant IDH blocks hepatocyte differentiation through the production of 2-HG and the suppression of HNF-4α, 
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the main regulator of hepatocytes identity and quiescence [90]. Farshidfar et al. have associated mutant IDH 
with a specific gene signature characterized by high mitochondrial and low chromatin modifier gene 
expression. Speculating about the significance of this signature is complex for the wide number of genes and 
processes involved. Potentially, the combination of anti-IDH targeted therapies with anti-mitochondrial activity 
drugs could be exploited in the future as a therapeutic strategy [91]. 
• 6.4 Angiogenesis and tumor environment. 
VEGF has a central role in carcinogenesis and it has been targeted in different malignancies. In CCA, VEGF 
expression is reported in about 30-40% of cases and is correlated with lymph node metastasis and poor 
prognosis [38]. VEGF expression is reported in 50% of GBC and also in this sub-group a poor prognosis is 
observed [39]. 
BTC have a characteristic hypovascular, desmoplastic stroma that plays an important role in tumor 
pathogenesis and is consisting of cancer associated fibroblasts (CAF) expressing α-smooth muscle actin (α-
SMA), activated macrophages and a fibrotic collagen rich extracellular matrix [92]. 
α-SMA positive CAFs are involved in cancer progression through production of matricellular proteins, growth 
factors, chemokines, and matrix metalloproteinases. Patients expressing high levels of α-SMA have poorer 
survival [93]. The desmoplastic matrix also allows the development of a niche fostering tumor spread rather 
than as a response to the anticancer treatments [94]. Transforming growth factor β (TGF- β) seems to be 
implicated in the generation of the niche. Indeed, preclinical models have demonstrated a reduction in fibrosis 
and tumor spread with TGF-β antagonist [95]. 
 
CAFs produce numerous factors involved in autocrine and paracrine signalling that promote oncogenic 
processes like periostin, tenascin-c, thrombospandin 1, stromal cell derived factor 1 (SDF-1), HGF and Wnt 
inducible signalling protein-1v (WISP1) [93]. These interact with cell signalling pathways. For example, periostin 
interacts with tenascin-C, HGF and SDF-1, which bind to their respective receptors, integrin, MET and CXCR4 on 
CCA cells, leading to activation of the PIK3CA/AKT signalling pathway. 
Finally, desmoplastic stroma may be influenced also by sonic Hedgehog (Hh) signalling pathway. Preclinical 
models have disclosed the interplay between Hh and CAF through platelet-derivated growth factor BB [96].  
Cancer associated macrophages (CaM) are implicated in formation and maintaining of the stromal 
microenvironment and appear to have prognostic significance.  A high number of CD163+ macrophages in the 
stroma of resected IH-CCA correlates with poor disease-free survival [97]. 
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Desmoplastic stroma formation is also associated with increased level of IL-6 that promotes tumor growth via 
autocrine and paracrine mechanisms [93]. 
For all these reasons, targeting stromal factors involved in cholangiocarcinogenesis or improving drug delivery 
through the desmoplastic stroma are attractive targets for novel therapeutics. 
• 6.5 Immune system. 
In BTC, a number of clinical and epidemiological factors might predict the efficacy of immunotherapies coexist. 
Several chronic infections, such as viral hepatitis and bacterial cholangitis, are established risk factors for 
cholangiocarcinoma. Notably, immunotherapies have shown promising efficacy in cancer associated with 
infections, probably thanks to the presentation of non-self or neoantigens related with infections [98]. 
Furthermore, in a patient subgroup of BTC with poor prognosis has been revealed had a high mutational load, 
resulting in abundant tumor-specific neoantigens, and enrichment for expression of immune-related genes, 
including genes encoding inhibitory immune-checkpoint proteins [65]. In these patients, immune-checkpoint 
inhibition could permit to overcome cancer related mechanism of immune-silencing. 
A central role in immune response is played by CaM that, through the production of soluble factor such as 
interleukins or cytokines, modulates anticancer immune response and maintain stromal environment [97]. 
In some small studies, programmed death-ligand 1 (PD-L1) expression has been evaluated on cancer specimens 
and on immune cells within the tumor microenvironment [99, 100]. PD-L1 is on  of the most studied biomarker 
and levels of tumor PD-L1 expression have been associated with sensitivity to immune checkpoint inhibitor 
monotherapy in several tumor and they could predict response to the immunotherapies. 
 
7- Competitive environment and pPotential development issues 
• 7.1 HER2 
HER2 also belongs to the ErbB family of tyrosine kinases receptor and it is seems to be overexpressed in 
approximately 10% of GBC and 26.3% EH-CCA [25]. Given the efficacy of agents targeting HER2 in other cancers 
types, they were tested in BTC patients, nevertheless none improved outcomes so far. 
Lapatinib is a dual tyrosine kinase EGFR and HER2 inhibitor; it was tested in two phase II studies in patients 
with advanced BTC. The first one was conducted on hepatobiliary cancer patients including 19 BTC, reaching  
poor results (mPFS was 1.8 months and mOS was 5.2 months) and no objective responses [101]. Later, similar 
results have emerged from a phase II trial involving only BTC patients: the response was extremely poor (0%), 
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leading to premature discontinuation of the trial [102]. The role of Trastuzumab, a mAb that targets the HER2 
receptor, is so far not well defined in treatment of BTC. The only data available comes from a retrospective 
analysis in which Javle et al. studied BTC patients with HER2 genetic alterations or protein overexpression 
treated with HER2-directed therapy in combination with concurrent therapy of physician’s choice. Among the 
eight GBC patients who received trastuzumab, one patient experienced complete response (CR), four patients a 
partial response (PR), and three had stable disease (SD). The median duration of response in these patients was 
40 weeks. In contrast, among five CCA patients no response was observed and disease progression occurred 
during treatment with trastuzumab [103]. Likewise, in 2012 Law reported a case of a patient affected by HER2 
positive GBC, showing a dramatic response after nine weeks of treatment with trastuzumab and paclitaxel 
[104]. 
Neratinib, a more recent tyrosine kinase inhibitor HER2-directed is actually under evaluation in SUMMIT, an 
ongoing basket trial involving a variety of tumor types harboring HER2 mutations, including BTC 
(NCT01953926). Preliminary data, recently presented during the American Association for Cancer Research's 
Annual Meeting 2017 showed an ORR of 22% in BTC (9 patients) [105]. 
Similarly, in a phase II trial evaluating the efficacy of Afatinib - a potent, orally bioavailable ErbB Family Blocker 
– was tested in different malignancies including 5 BTCs presenting HER2 amplification [106]. As shown in table 
1, afatinib is currently under evaluation, in association with capecitabine, in a phase I/Ib trial addressed to 
patients with advanced refractory solid tumors, comprising pancreatic cancer and BTCs (NCT02451553) (Table 
1, New therapies under evaluation in biliary tract cancers). 
Given these contradictory outcomes, HER2-directed therapy remains an open chance of treatment for BTC 
patients with gene amplification, especially in GBC. A phase II trial of trastuzumab-emtansine is currently 
ongoing in HER2-positive BTC patients (NCT02999672). (Table 1). New therapies under evaluation in biliary 
tract cancers)  
 
• 7.2 PIK3CA/PTEN/AKT/mTOR pathway 
The PIK3CA/PTEN/AKT/mTOR pathway has drawn attention in last years as a target for new drugs 
development. About 12.5% of GBC patients have activating mutations of PIK3CA [107]. 
In a phase II Italian study, 39 patients with advanced and pre-treated BTC received everolimus - an mTOR 
inhibitor; mPFS was 3.2 months, and mOS was 7.7 months [108]. Since only patients who had received no more 
than one previous systemic chemotherapy regimen were enrolled, these results are at least in line with 
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conventional 2
nd
-line chemotherapy results in advanced BTC, reporting a mPFS and mOS of 2.8 and 7.5 months 
respectively. 
At the same time, in the Australian phase II study, everolimus was investigated in the first line setting in 
advanced BTC. Final results are not yet available, but preliminary findings are encouraging:  ORR of 12 % and  
mPFS of 6.0 months [109]. 
More extensive studies are needed to clarify the efficacy of mTOR inhibitors in the treatment of BTC. 
As shown in table 1, a phase II trial using a PIK3CA inhibitor, copanlisib in CCA, in first line setting in 
combination with cisplatin and gemcitabine is ongoing (NCT02631590) Table 1. 
• 7.3 BRAF 
BRAF mutations occur in a small portion of BTC patients; the most common mutation is V600E, whose 
frequency range from 5 to 8% [110]. 
In the study of Hyman the efficacy of vemurafenib was evaluated in non-melanoma cancers. In the cohort of 8 
CCA patients harboring BRAF V600E mutation, it was described one PR, which have persisted for more than 12 
months, four SD and three progression disease (PD) [111]. 
Furthermore, given the impressive activity noted in metastatic melanoma with BRAF V600 mutations using a 
combination of dabrafenib (BRAF inhibitor) and trametinib (MEK1 and MEK2 inhibitor), dual blockade merits 
evaluation also in this subset. A case report of a notable response in a IH-CCA patient who received this 
combination supports this hypothesis [112]. 
• 7.4 ROS, ALK, NTRK 
The presence of NTRK fusions in patients diagnosed with IH-CCA have been stated around 3.5% [113]. Sporadic 
fusions of ROS1 (up to 8.7%) and ALK (2.6%) are also described [114]. 
Compounds targeting an NTRK1/2/3, ROS1, or ALK gene rearrangement have demonstrated impressive ORR 
(57-86%) in a selected population of solid tumors [115]. 
Based on this data and the well-known clinical activity of ALK inhibitors in non-small cell lung cancer (NSCLC) 
with ALK or ROS1 translocation, a phase II trial is ongoing. This trial evaluates the efficacy and safety of ceritinib 
in patients with IH-CCA over-expressing ROS1 or ALK (NCT02374489). The recently identified FIG-ROS fusion 
suggests that crizotinib therapy merits evaluation: NCT02034981 is a phase II trial of crizotinib in patients 
harbouring an ALK, MET, or ROS1 alteration (Table 1). 
During the most recent ASCO annual meeting, the presentation of preliminary data on larotrectinib showed a 
consistent and durable antitumor activity of this drug in NTRK fusion cancers, across a wide range of tumor 
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types. Among 55 NTRK fusion patients enrolled, 2 were CCA. The ORR for the 46 patients evaluated was 78%, 
with responses in 12 tumor types; no data on CCA were presented [116]. 
• 7.5 FGFR 
FGFR pathway is involved in cellular migration, proliferation, survival, and differentiation. FGFR mutations and 
fusions predominate in IH-CCA in about 16% of cases [110]. In particular, genome-wide structural analyses 
showed numerous translocation events concerning the FGFR2 locus, ranging between 11 and 45% in IH-CCA 
patients [117]. The discovery of recurrent FGFR aberrations has opened a promising therapeutic avenue.  
BGJ 398, an oral FGFR inhibitor, is under evaluation in a phase II trial in advanced CCA with FGFR gene 
fusion/translocation after first-line chemotherapy (NCT02150967). The recent interim report of this trial was 
the following: 50 patients with BTC having FGFR genetic alterations were enrolled, the majority with IH-CCA. 
The ORR was 22% (all 8 patients with a partial response had an FGFR2 fusion) and the disease control rate 
(DCR) was 95% with PFS of 6 months [103].  
A number of other clinical trials involving selective FGFR small molecule inhibitors - including INCB54828 
(NCT02924376), BAY1163877 (NCT01976741), and the irreversible FGFR inhibitor TAS-120 (NCT02052778) - are 
currently in progress in early-phase trials in patients with advanced solid tumors, including BTC (Table 1). 
Moreover, nonselective multi-TKIs targeting also FGFR, including ponatinib and pazopanib, have showed some 
activity in patients with highly pretreated IH-CCA [117]. 
Finally, a nonselective TKI, ARQ 087 (NCT01752920), which inhibits RET, PDGF receptor, KIT, SRC, and FGFR1–3, 
is currently under evaluation in a phase II trial of patients with FGFR-aberrant tumors, including FGFR2 fusion–
positive advanced IH-CCA. Preliminary data from the phase I/II basket trial show that 3 of the 12 IH-CCA 
patients with FGFR2 fusion had a PR (DCR of 75%). 
In conclusion, the preliminary data for FGFR inhibitors in advanced IH-CCA are encouraging. 
• 7.6 IDH1-2 
IDH 1 and 2 mutations are frequent in IH-CCA (9 of 40, 23%), while lacking in EH-CCA and GBC patients. 
Additionally, results from several researches have shown that IDH1 mutation is more common than mutation 
of IDH2. 
Recently the findings of a dose escalation study of AG-120, an IDH1 inhibitor, in patients with advanced solid 
tumors having these mutations was presented by Burris et al. Of the 20 IH-CCA patients enrolled, 1 patient 
(5%) reached a PR and 11 patients (55%) had SD, with disease stability beyond 6 months [118]. 
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As shown in table 1, tThe potential efficacy of IDH1 and IDH2 inhibitors is currently being evaluated in clinical 
trials involving solid tumors such as BTC that harbor these mutations (NCT02481154, NCT02073994, 
NCT02381886). Table 1 
• 7.7 Immunotherapy 
Mechanisms involved in DNA repair are indispensable for the maintenance of genomic stability. Acquired or 
genetic mutations leading to defective DNA mismatch repair (MMR) are common in several tumors such as 
colorectal, gastric and endometrial cancer [110]. 
In the study of Jaivle et al regarding mutational profiling of BTC, mutations in genes involved in DNA repair - 
MSH6, BRCA1, BRCA2, ATM, MLH1 or MSH2 - was highly represented: 13% in IH-CCA, 26% in EH-CCA and 6% of 
GBC cases [103].  
Available data comes from KEYNOTE-028, an ongoing, phase 1b trial of pembrolizumab monotherapy for 
advanced solid tumors PD-L1-positive. Patients with PD-L1-positive BTC were included, with the exception of 
cancer of the ampulla of Vater. Of 89 BTC patients screened for PD-L1 expression, 42% were PD-L1-positive 
tumors. 24 pretreated patients - including 38% who received ≥3 prior therapies - were enrolled, showing an 
ORR (confirmed and unconfirmed) of 17%, with 4 PR, 4 SD, and 12 PD [119]. 
Given the demonstrated sensibility to programmed cell death protein 1 (PD-1) blockade with checkpoint 
inhibitor agents (e.g pembrolizumab or nivolumab), BTC patients presenting these mutations can represent a 
subset where immunotherapy may be effective. A number of immunotherapy studies are currently recruiting 
(Table 1). 
 
8-Conclusion  
Treatment for advanced BTC is challenging; although cisplatin and gemcitabine are considered the standard 1
st
 
line on the basis of a consolidated phase III study, survival outcomes remain dismal; TCR is achieved in 
approximately 80% of cases, but mOS is generally less than one year. Second-line treatment should be offered 
to patients who maintain a good PS, but no schedule should be preferred above the others. To date, there is no 
strong evidence to support the use of combination instead of single-agent therapy neither. Data from 
retrospective series show that 2
nd
 line treatment yields mPFS of 3 months and mOS of 7 months approximately. 
Moreover, treatment of BTC patients is encumbered with a high rate of complications, such as infections, need 
of biliary stenting, gastrointestinal toxicity, that have a high burden not only on patient’s care but also on social 
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and economical aspects. It goes without saying that every patient should be carefully evaluated for potential 
risks and benefit of active therapy and that every treatment, in addition to efficacy, should provide a 
manageable safety profile. 
In the past years, despite initial encouraging reports, targeted agents have failed to provide significant changes 
in the history of BTC patients. In particular, anti-EGFR and anti-VEGF treatment used in addition to cisplatin and 
gemcitabine as 1
st
 line treatment have provided no benefit in randomized control trials. Other targeted agents 
used, such as anti-MEK or anti-HER2, and data from some small non-randomized trials have shown little value 
and conflicting results. More recently, some other druggable targets are raising renewed interest in tailored 
medicine for BTC care. 
9-Expert opinion  
Despite a great effort to improve patients’ outcomes, in the past decades only few studies have provided 
practice-changing findings. The milestones of BTC care include the superiority of chemotherapy over BSC [12] 
and the identification of gemcitabine-cisplatin as standard treatment for advanced disease [10]. More recently, 
the role of adjuvant chemotherapy after resection of localized disease is being supported by randomized 
controlled trials [9]. These results have been achieved over a period of about 20 years and appear inadequate 
considering the progresses that have been made in other diseases, including gastrointestinal malignancies, in 
the same time span.  
Undoubtedly, dealing with a rare disease is the main disadvantage researchers have to face when designing 
clinical trials; in the 90ies BTCs were often grouped with ampullary and pancreatic cancers. The bulk of 
literature available includes small trials that, in spite of being multicentric, generally have a small sample size of 
40-100 patients. In addition, some of the first studies with targeted therapies were not supported by a strong 
rationale or an accurate patient selection; in some cases, researchers have tried to apply the same paradigms 
that showed success in other cancer types to BTC, an orphan disease with very few options. 
We have already pointed out that the different entities that are commonly included in BTC, such as IH-CCA, EH-
CCA e GBC, have also different clinical and molecular features. Sometimes they are used as stratification factors 
for randomization or to conduct subgroup analyses. In our opinion, this issue is a great limitation especially for 
studies with targeted agents because the different pathways activated or inhibited are strongly influenced by 
the molecular features of the tumor, which vary strongly among the entities. For example, in the first studies 
with anti-EGFR therapies, slightly better results were observed in the IH-CCA groups, but their real impact was 
never significant because of the small sample size or the retrospective character of the analyses. 
With the advent of new, advanced technologies like next-generation sequencing the underpinnings of genomic 
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landscape of BTCs are being disclosed. To date, no distinct molecular mutation characterizes BTCs, but the 
scenario is scattered into several alterations that have a relatively low rate, especially if we consider the 
different anatomical locations. Among the druggable alterations, IDH1-2 mutations and FGFR translocations are 
those that show the most potential because of higher frequency and the investigation of different compounds 
in clinics. 
In parallel with the progress of technologies, drug development in the past few years is substantially changing; 
trial design is moving from the standard approach from phase I to phase III trials and approval, to newest 
methods. More often we are observing proof-of-concept studies that lead to an accelerated approval by 
regulatory agencies, thanks to striking results on a limited number of patients in non-randomized phase I or II 
trials.  
Moreover, revolutionary trials designs permit to handle multiple related questions with fewer patients. In 
basket trials the effect of one drug is tested at the same time but in a variety of tumor types that share the 
same single mutation. Umbrella trials indeed have many different treatment arms within one trial; people are 
assigned to a particular treatment arm of the trial based on their type of cancer and the specific molecular 
makeup of their disease.  
Nivolumab and pembrolizumab have recently been granted FDA approval for microsatellite instability-high 
(MSI-H) tumors; this is the first time a cancer treatment to be approved based on a common biomarker rather 
than tumor type. A percentage of BTCs patients are potentially involved by this progress: similarly, some 
ongoing basket trials that we have introduced in the previous paragraphs, such as those directed against ROS, 
ALK, NTRK1/2/3 are deemed to provide interesting results for patients harboring low-frequency mutations. 
Thanks to these new approaches and to the better knowledge of potentially actionable genomic alterations in 
BTCs it will be possible to offer a chance for tailored medicine to BTCs patients ant to and to meet an unmet 
clinical need. 
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